Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New screening platform aims to match cancer patients to the right trial

NCT ID NCT05419375

Knowledge-focused Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a screening platform to check tumor tissue for specific biomarkers. The goal was to see if patients with solid tumors could be eligible for a linked Roche clinical trial. About 470 participants provided tumor samples for testing. The study is now complete and focused on identifying eligible patients, not on giving treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

470 people

The number who actually took part.

Started

Jul 2022

Finished

Sep 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

General Inclusion Criteria: * Confirmed availability of a representative formalin-fixed, paraffin-embedded (FFPE) tumor specimen meeting criteria defined in the protocol * Considered by principal investigator (PI) to be a candidate for a linked clinical trial with an investigational medicinal product, and that the participant has the awareness and willingness to participate in said trial Inclusion Criteria for Participants with Stage III NSCLC * Locally advanced, unresectable Stage III NSCLC of either squamous or non-squamous histology based on 8th edition of the American Joint Committee on Cancer (AJCC) and Union for International Cancer Control (UICC) cancer staging system * Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 Inclusion Criteria for Participants with Stage II, IIIA, or Select IIIB (T3N2 only) NSCLC Requiring Adjuvant Treatment * Stage II, IIIA, or select IIIB (T3N2 only) NSCLC based on the 8th edition of the AJCC and UICC cancer staging system (Amin et al. 2017) * Considered eligible for curative intent surgery (complete resection with all surgical margins testing negative for tumor) * Screening within Study BX43361, using a pretreatment biopsy, is encouraged to be performed as early in the participant treatment pathway as possible to ensure the participant is potentially eligible for all cohorts, and should meet guidelines as defined by the protocol * Representative FFPE tumor specimen obtained prior to the start of any treatment * ECOG Performance Status of 0 or 1 General Exclusion Criteria: * History of malignancy other than NSCLC within 5 years prior to screening, except for malignancies with a negligible risk of metastasis or death * Any condition that may affect the interpretation of study results * Significant liver or cardiovascular disease * Prior allogenic stem-cell or solid-organ transplantation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-small cell lung cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Solid tumors

Contacts and locations

Locations

  • Aichi Cancer Center Hospital

    Aichi, 464-8681, Japan

  • Asan Medical Center

    Seoul, 05505, South Korea

  • Asklepios Klinik Gauting

    München-Gauting, 82131, Germany

  • Ataturk Sanatoryum Egitim Ve Arastirma Hastanesi

    Ankara, 06280, Turkey (Türkiye)

  • Ataturk University Medical Faculty Yakutiye Research Hospital Medical Oncology Department

    Erzurum, 25240, Turkey (Türkiye)

  • Auckland City Hospital, Cancer and Blood Research

    Auckland, 1023, New Zealand

  • Azienda Ospedaliera San Camillo Forlanini

    Rome, Lazio, 00152, Italy

  • Bakirkoy Dr. Sadi Konuk Egitim ve Arastirma Hastanesi, Tibbi Onkoloji

    Bakirkoy / Istanbul, 34147, Turkey (Türkiye)

  • Barts & London School of Med

    London, EC1A 7BE, United Kingdom

  • COT - Centro Oncologico do Triangulo

    Uberlândia, Minas Gerais, 38408-150, Brazil

  • Central Chest Institute of Thailand

    Nonthaburi, 11000, Thailand

  • Centre Leon Berard

    Lyon, 69008, France

  • Centro de Estudios Clínicos SAGA

    Santiago, Chile

  • Centro de Investigación Oncologica Galerias

    Aguascalientes, 20124, Mexico

  • Chang Gung Memorial Hospital - Linkou

    Taoyuan, 333, Taiwan

  • Chonnam National University Hwasun Hospital

    Jeollanam-do, 58128, South Korea

  • Clinica CIMCA

    San José, 10103, Costa Rica

  • Clinica De La Costa

    Barranquilla, 080020, Colombia

  • Clinstile S.A de C.V.

    Mexico City, Mexico CITY (federal District), 06700, Mexico

  • Clínica de Oncologia Reichow

    Blumenau, Santa Catarina, 89010-340, Brazil

  • Dicle University Faculty of Medicine

    Diyarbakır, 21280, Turkey (Türkiye)

  • Dolno?l?skie Centrum Chorób P?uc we Wroc?awiu

    Wroc?aw, 53-439, Poland

  • Gazi Uni Medical Faculty Hospital

    Ankara, 06500, Turkey (Türkiye)

  • Hia Sainte Anne

    Toulon, 83041, France

  • Hospital Medical Center Bezanijska kosa

    Belgrade, 11080, Serbia

  • Hospital Regional Universitario Carlos Haya

    Málaga, 29010, Spain

  • Hospital Universitario San Ignacio

    Bogotá, 000472, Colombia

  • Hospital de Clínicas de Porto Alegre X

    Porto Alegre, Rio Grande do Sul, Brazil

  • ICIMED Instituto de Investigación en Ciencias Médicas

    San José, 10108, Costa Rica

  • Institute for pulmonary diseases of Vojvodina

    Kamenitz, 21204, Serbia

  • Instituto Cancerología Medellin

    Medellín, 050024, Colombia

  • Instituto do Cancer do Estado de Sao Paulo - ICESP

    São Paulo, São Paulo, 01246-000, Brazil

  • Kagoshima University Hospital

    Kagoshima, 890-8520, Japan

  • Kangbuk Samsung Hospital

    Seoul, 03181, South Korea

  • Kindai University Hospital

    Ōsaka-sayama, 589-8511, Japan

  • Klinikum rechts der Isar der TU Muenchen

    München, 81675, Germany

  • Kobe City Medical Center General Hospital

    Hyōgo, 650-0047, Japan

  • Komagome Hospital

    Tokyo, 113-8677, Japan

  • Korea University Guro Hospital

    Seoul, 08308, South Korea

  • Liv Hospital Ankara

    Ankara, 06680, Turkey (Türkiye)

  • Maastricht University Medical Center

    Maastricht, 6229 HX, Netherlands

  • Marmara Uni Faculty of Medicine

    Istanbul, 34890, Turkey (Türkiye)

  • Medanta -The Medicity

    Gurgaon, Haryana, India

  • Medical Park Seyhan Hospital

    Seyhan, 01140, Turkey (Türkiye)

  • Medikal Park Samsun

    Samsun, 55200, Turkey (Türkiye)

  • Medipol University Medical Faculty

    Istanbul, 34214, Turkey (Türkiye)

  • National Cancer Institute

    Bangkok, 10400, Thailand

  • National Cheng Kung Univ Hosp

    Tainan, 00704, Taiwan

  • National Hospital Organization Himeji Medical Center

    Hyōgo, 670-8520, Japan

  • National Taiwan Uni Hospital

    Taipei, 10041, Taiwan

  • Northwest Cancer Specialists

    Vancouver, Washington, 98686, United States

  • Oncoclinicas Rio de Janeiro S.A.

    Rio de Janeiro, 22250-905, Brazil

  • Oncology & Hematology Associates of Southwest Virginia, Inc

    Blacksburg, Virginia, 24060, United States

  • Oncology Unit, Faculty of Medicine, Vajira Hospital

    Dusit, 10300, Thailand

  • One Clinical Research

    Nedlands, Western Australia, 6009, Australia

  • Pusan National University Yangsan Hospital

    Gyeongsangnam-do, 50612, South Korea

  • Queen Mary Hospital

    Hong Kong, Hong Kong

  • Rajavithi Hospital

    Bangkok, 10400, Thailand

  • Rambam Medical Center

    Haifa, 3109601, Israel

  • RedSalud Vitacura

    Santiago, Chile

  • Santa Casa de Misericordia de Porto Alegre

    Porto Alegre, Rio Grande do Sul, 90050-170, Brazil

  • Seoul National University Bundang Hospital

    Seongnam-si, 13605, South Korea

  • Shizuoka Cancer Center

    Shizuoka, 411-8777, Japan

  • Siriraj Hospital

    Bangkok, 10700, Thailand

  • Songklanagarind Hospital

    Songkhla, 90110, Thailand

  • Srinagarind Hospital

    Khon Kaen, 40002, Thailand

  • Sunnybrook Health Sciences Centre

    Toronto, Ontario, M4N 3M5, Canada

  • Taichung Veterans General Hospital

    Xitun Dist., 40705, Taiwan

  • Taipei Medical University Hospital

    Taipei, 110, Taiwan

  • Taipei Municipal Wan Fang Hospital

    Taipei, 119, Taiwan

  • Taipei Veterans General Hospital

    Taipei, 11217, Taiwan

  • Tan Tock Seng Hospital

    Singapore, 308433, Singapore

  • Texas Oncology, P.A.

    Austin, Texas, 78745, United States

  • Texas Oncology- Northeast Texas

    Tyler, Texas, 75702, United States

  • The Cancer Institute Hospital of JFCR

    Tokyo, 135-8550, Japan

  • Thompson Cancer Survival Center

    Knoxville, Tennessee, 37916-2305, United States

  • Tottori University Hospital

    Tottori, 683-8504, Japan

  • Univ Clinical Center Kragujevac

    Kragujevac, 552302, Serbia

  • University Clinical Centre of Serbia

    Belgrade, 11030, Serbia

More trials for these conditions

Other studies related to the condition(s) this trial covers.